BHVN - CIK 0001935979
Biohaven Ltd. trades as BHVN and has a market capitalization of $1.64 B, making it the #2254 largest US-listed company by market value. This page tracks Biohaven Ltd. through 266 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Major company event | 8-K | 2026-05-05 |
| Quarterly report | 10-Q | 2026-05-04 |
| Major company event | 8-K | 2026-05-04 |
| Major company event | 8-K | 2026-05-04 |
| Prospectus supplement | 424B5 | 2026-05-04 |
| S-3ASR | - | 2026-05-04 |
| Insider trade | 4 | 2026-04-30 |
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and nonclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA (spinocerebellar ataxia); myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules and antibody drug conjugates for cancer. For more information, visit www.biohaven.com .
Conference call and webcast to be held Monday, September 23 , at 8:30am ET
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
The largest companies sharing Biohaven Ltd.'s SEC industry classification (pharmaceutical preparations).
Biohaven Ltd. (BHVN) has a market capitalization of $1.64 B as of 2026-06-10, ranking #2254 among US-listed companies.
In its latest fiscal year Biohaven Ltd. reported a net loss of $738.82M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.